The inhibition of glutamine-fructose-6-phosphate aminotransferase activity downregulates GRP78 expression and activates IRE1α, which leads to the increased sensitivity of non-small-cell lung cancer (NSCLC) cells to cisplatin and further initiates the apoptotic pathway (Chen et al., 2019). The gene discussed is ERN1; the disease is non-small cell lung carcinoma.